IL310975A - LOU064 for the treatment of multiple sclerosis - Google Patents
LOU064 for the treatment of multiple sclerosisInfo
- Publication number
- IL310975A IL310975A IL310975A IL31097524A IL310975A IL 310975 A IL310975 A IL 310975A IL 310975 A IL310975 A IL 310975A IL 31097524 A IL31097524 A IL 31097524A IL 310975 A IL310975 A IL 310975A
- Authority
- IL
- Israel
- Prior art keywords
- lou064
- multiple sclerosis
- treating multiple
- treating
- sclerosis
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240444P | 2021-09-03 | 2021-09-03 | |
| US202163282363P | 2021-11-23 | 2021-11-23 | |
| US202263304106P | 2022-01-28 | 2022-01-28 | |
| US202263353866P | 2022-06-21 | 2022-06-21 | |
| US202263369008P | 2022-07-21 | 2022-07-21 | |
| PCT/IB2022/058205 WO2023031840A1 (en) | 2021-09-03 | 2022-09-01 | Lou064 for treating multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310975A true IL310975A (en) | 2024-04-01 |
Family
ID=83438454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310975A IL310975A (en) | 2021-09-03 | 2022-09-01 | LOU064 for the treatment of multiple sclerosis |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240350489A1 (https=) |
| EP (1) | EP4395779A1 (https=) |
| JP (2) | JP7564347B2 (https=) |
| KR (1) | KR20240055038A (https=) |
| AU (1) | AU2022337087A1 (https=) |
| CA (1) | CA3229887A1 (https=) |
| IL (1) | IL310975A (https=) |
| MX (1) | MX2024002581A (https=) |
| TW (1) | TW202310841A (https=) |
| WO (1) | WO2023031840A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| EP4522170A1 (en) * | 2022-05-13 | 2025-03-19 | Principia Biopharma Inc. | Bruton tyrosine kinase inhibitors for use in the treatment of myelin oligodendrocyte glycoprotein antibody disease (mogad) |
| CN119744171A (zh) * | 2022-06-24 | 2025-04-01 | 默克专利股份公司 | 自身免疫病和炎性疾病的治疗方案 |
| US20250243170A1 (en) * | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130197080A1 (en) * | 2010-08-02 | 2013-08-01 | Sanofi | Use of teriflunomide for treating multiple sclerosis |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| MX2020007312A (es) * | 2018-01-08 | 2021-01-08 | G1 Therapeutics Inc | Regimenes de dosificacion superior de g1t38. |
| US12109193B2 (en) * | 2018-07-31 | 2024-10-08 | Loxo Oncology Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
| MX2021014161A (es) | 2019-05-23 | 2022-01-04 | Novartis Ag | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. |
| HRP20251001T1 (hr) | 2019-05-23 | 2025-10-24 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije |
| BR112021023054A2 (pt) | 2019-05-23 | 2022-03-29 | Novartis Ag | Formas cristalinas de um inibidor de btk |
| WO2022081512A1 (en) * | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
| TWI905371B (zh) * | 2021-01-26 | 2025-11-21 | 瑞士商諾華公司 | 藥物組成物 |
| EP4301365A1 (en) * | 2021-03-03 | 2024-01-10 | Janssen Pharmaceutica NV | Combination therapy using a malt1 inhibitor and a btk inhibitor |
-
2022
- 2022-09-01 TW TW111133216A patent/TW202310841A/zh unknown
- 2022-09-01 CA CA3229887A patent/CA3229887A1/en active Pending
- 2022-09-01 JP JP2023517239A patent/JP7564347B2/ja active Active
- 2022-09-01 US US18/685,551 patent/US20240350489A1/en active Pending
- 2022-09-01 EP EP22777001.3A patent/EP4395779A1/en active Pending
- 2022-09-01 WO PCT/IB2022/058205 patent/WO2023031840A1/en not_active Ceased
- 2022-09-01 KR KR1020247010451A patent/KR20240055038A/ko active Pending
- 2022-09-01 MX MX2024002581A patent/MX2024002581A/es unknown
- 2022-09-01 IL IL310975A patent/IL310975A/en unknown
- 2022-09-01 AU AU2022337087A patent/AU2022337087A1/en active Pending
-
2024
- 2024-09-26 JP JP2024167085A patent/JP2024178420A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024002581A (es) | 2024-03-20 |
| KR20240055038A (ko) | 2024-04-26 |
| TW202310841A (zh) | 2023-03-16 |
| EP4395779A1 (en) | 2024-07-10 |
| JP2023542878A (ja) | 2023-10-12 |
| JP2024178420A (ja) | 2024-12-24 |
| US20240350489A1 (en) | 2024-10-24 |
| AU2022337087A1 (en) | 2024-03-14 |
| JP7564347B2 (ja) | 2024-10-08 |
| WO2023031840A1 (en) | 2023-03-09 |
| CA3229887A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL310975A (en) | LOU064 for the treatment of multiple sclerosis | |
| IL287907A (en) | Cancer treatment methods | |
| IL288201A (en) | Dental care device | |
| SG11202100682YA (en) | Method for treating epilepsy | |
| SG11202108029XA (en) | Methods of treating multiple myeloma | |
| GB2600737B (en) | Robotic surface treating system | |
| GB2600738B (en) | Robotic surface treating system | |
| IL316747A (en) | Lymphoma treatment methods | |
| GB201909468D0 (en) | Compounds for treating cancer | |
| PL4080313T3 (pl) | Instalacja przetwarzająca do obróbki przedmiotów | |
| PL4048284T4 (pl) | Metoda leczenia nowotworów | |
| IL289824A (en) | Methods of treating multiple sclerosis | |
| IL290319A (en) | Compound for combined treatment | |
| IL284668A (en) | Methods of treating schizophrenia | |
| GB2600735B (en) | Robotic surface treating system | |
| GB2600739B (en) | Robotic surface treating system | |
| GB2600736B (en) | Robotic surface treating system | |
| GB2600734B (en) | Robotic surface treating system | |
| PL3733489T3 (pl) | Instalacja do obróbki przedmiotów obrabianych | |
| SG11202107355RA (en) | Improved method and compositions for surface treatment | |
| HK40106430A (en) | Lou064 for treating multiple sclerosis | |
| GB202006236D0 (en) | New treatment | |
| GB201909466D0 (en) | Compounds for treating cancer | |
| GB202007652D0 (en) | Compounds for treating covid-19 | |
| GB201908436D0 (en) | Compounds for treating multiple myeloma |